Hepatocellular Carcinoma Monitored by F-18 Fluorodeoxyglucose Positron Emission Tomography After Laparoscopic Microwave Coagulation Therapy

• Published in: Clinical nuclear medicine 1999-07, Vol.24 (7), p.536-538
• Main Authors: MORIKAWA, HIROYASU, SHIOMI, SUSUMU, SASAKI, NOBUMITSU, JOMURA, HISATO, SAKAGUCHI, HIROKI, NISHIGUCHI, SHUHEI, SEKI, SUICHI, KUROKI, TETSUO, KUBO, SHOJI, KAWABE, JOJI, OCHI, HIRONOBU
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Carcinoma, Hepatocellular - diagnostic imaging; Carcinoma, Hepatocellular - therapy; Female; Fluorodeoxyglucose F18; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Liver Neoplasms - diagnostic imaging; Liver Neoplasms - therapy; Liver. Biliary tract. Portal circulation. Exocrine pancreas; Magnetic Resonance Imaging; Medical sciences; Microwaves - therapeutic use; Middle Aged; Tomography, Emission-Computed; Tumors
• ISSN: 0363-9762; 1536-0229
• DOI: 10.1097/00003072-199907000-00021

A 46-year-old woman was hospitalized for treatment of hepatocellular carcinoma. On admission, positron emission tomography with F-18 fluorodeoxyglucose (FDG PET) showed a hot spot that coincided with the tumor; its standardized uptake value (SUV) was 5.47. Two weeks and 6 months after laparoscopic microwave coagulation therapy, FDG PET showed a reduction in radioactive uptake to less than the background level, and the SUVs were 0.46 and 0.50, respectively. FDG PET performed 18 months after treatment showed a hot spot on the abdominal side of the site treated previously, and the SUV was 3.19. However, CT and MRI showed no evidence of recurrence. Our findings indicate that FDG PET is useful for evaluating the response to treatment and disease recurrence in patients with hepatocellular carcinoma.